Egetis Therapeutics (EGTX) Q4 2025 earnings summary

Executive summary

• Emcitate received EU approval as the first treatment for MCT8 deficiency, launched in Germany in May 2025, and obtained FDA Breakthrough Therapy designation; U.S. rolling NDA was completed in January 2026, with FDA decision expected by September 2026.

• Revenue for 2025 reached SEK 62.4 million, a 40% increase year-over-year at constant exchange rates, driven by EU launch and expanded access agreements.

• Patient identification in the U.S. surpassed 140 by early 2026, up from 28 in 2022, with expanded access programs and 17 active specialist sites.

• Distribution partnerships and agreements expanded in Türkiye, Central/Eastern Europe, and the Gulf region, with first orders received and ongoing pricing/reimbursement processes in major EU markets.

• Positive results from the ReTRIACt study supported regulatory filings and new clinical data for RTH-beta; a directed share issue in October 2025 raised SEK 183 million, strengthening liquidity.

Financial highlights

• 2025 revenue: SEK 62.4 million (vs. SEK 46.1 million in 2024); Q4 revenue: SEK 17.9 million (vs. SEK 10.8 million in Q4 2024); net loss for the year was SEK -343 million (vs. SEK -344 million in 2024).

• Adjusted gross profit for 2025: SEK 49.6 million, with non-recurring R&D depreciation and milestone payments; adjusted gross margin was 79.5% (74.8% in 2024).

• Cash position at year-end: SEK 215.8 million (vs. SEK 351 million in 2024), supported by a SEK 183 million directed share issue.

• Cash flow from operations: SEK -227.9 million; debt repayments of SEK 29.3 million.

• Equity ratio at 53% (62% in 2024); earnings per share for the year SEK -0.9 (-1.1 in 2024).

Outlook and guidance

• FDA decision on Emcitate NDA expected in September 2026, with U.S. launch planned for Q4 2026, subject to approval.

• Priority Review Voucher monetization anticipated post-approval; continued investment in U.S. commercial infrastructure and patient identification.

• Further clinical development for Emcitate in RTH-beta under evaluation, with plans for a pivotal trial and indication expansion opportunities.

• Continued rollout and optimization of pricing and reimbursement in Europe.